Related Experiment Video
Updated: May 27, 2026

Isolation of Papillary and Reticular Fibroblasts from Human Skin by Fluorescence-activated Cell Sorting
Published on: May 7, 2019
Fibroblast growth factor 21 ameliorates psoriasiform inflammation and epidermal hyperplasia through the regulation of
Xueran Guan1, Xianrong Zhu2, Yuxin Lei2
1Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou 325035, Zhejiang Province, China; College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
Background:
Psoriasis is a chronic immune-mediated skin condition characterized by excessive epidermal growth and persistent inflammation. Although current therapies improve disease outcomes, limitations in long-term efficacy and safety remain. Fibroblast growth factor 21 (FGF21), involved in metabolic regulation, has been reported to display anti-inflammatory activity and support tissue homeostasis; however, its role in psoriasis is not fully understood.
Methods:
A psoriasis-like mouse model established by imiquimod (IMQ) application was used to assess the in vivo activity of FGF21. Histopathological examination, cytokine analysis, immunohistochemistry, and western blotting were conducted to assess epidermal alterations and signaling pathways. In vitro, lipopolysaccharide-stimulated HaCaT keratinocytes were used to examine the impact of FGF21 on cell proliferation, apoptosis, and inflammatory mediator expression, while primary normal human epidermal keratinocytes (NHEKs) were incorporated for validation. Furthermore, pathway alterations were evaluated, and pharmacological inhibition with chloroquine (CQ) was used to assess autophagy dependence.
Results:
FGF21 administration attenuated psoriasis-like skin lesions, reduced systemic inflammatory cytokine levels in IMQ-treated mice, and exhibited preliminary tolerability based on body weight and histology. In keratinocytes, FGF21 partially restored proliferation-apoptosis balance and suppressed inflammation, associated with reduced NF-κB activation. FGF21 also modulated autophagy-related proteins alongside PI3K/AKT inhibition, with increased SIRT1 expression and decreased STAT3 activation. Crucially, CQ perturbation revealed that the anti-inflammatory and anti-proliferative benefits of FGF21 depended on autophagy restoration.
Conclusions:
FGF21 modulates key inflammatory and autophagy-related signaling pathways in psoriasis-like mice model and may represent a promising therapeutic candidate in psoriasis and other autoimmune inflammatory disorders.
Insights
Fibroblast growth factor 21 (FGF21) reduced psoriasis symptoms by modulating inflammation and restoring autophagy. This suggests FGF21 as a potential therapy for psoriasis and other autoimmune diseases.
Area of Science:
- Dermatology
- Immunology
- Metabolic Regulation
Background:
- Psoriasis is a chronic immune-mediated skin disease with limited long-term treatment efficacy.
- Fibroblast growth factor 21 (FGF21) has known anti-inflammatory properties but its role in psoriasis is unclear.
Purpose of the Study:
- To investigate the therapeutic potential of FGF21 in a psoriasis-like mouse model.
- To elucidate the mechanisms underlying FGF21's effects on skin inflammation and epidermal homeostasis.
Main Methods:
- Utilized an imiquimod (IMQ)-induced psoriasis-like mouse model for in vivo studies.
- Conducted histopathological, cytokine, immunohistochemical, and Western blot analyses.
- Employed in vitro studies with HaCaT and primary human epidermal keratinocytes (NHEKs) to assess FGF21's impact on cellular processes and signaling pathways, including autophagy dependence via chloroquine (CQ) inhibition.
Main Results:
- FGF21 administration significantly reduced psoriasis-like skin lesions and systemic inflammation in mice.
- In keratinocytes, FGF21 suppressed inflammation by inhibiting NF-κB activation and restored proliferation-apoptosis balance.
- FGF21 modulated autophagy, PI3K/AKT, SIRT1, and STAT3 pathways, with its benefits contingent on autophagy restoration.
Conclusions:
- FGF21 demonstrates therapeutic potential by modulating inflammatory and autophagy-related pathways in psoriasis.
- FGF21 may serve as a promising therapeutic candidate for psoriasis and other autoimmune inflammatory conditions.
Related Concept Videos
Introduction to Fibroblasts
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
TGF - β Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
